122 related articles for article (PubMed ID: 37696420)
21. MYC Promotes LDHA Expression through MicroRNA-122-5p to Potentiate Glycolysis in Hepatocellular Carcinoma.
Wang X; Zhang P; Deng K
Anal Cell Pathol (Amst); 2022; 2022():1435173. PubMed ID: 36033372
[TBL] [Abstract][Full Text] [Related]
22. BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.
Zheng YH; Hu WJ; Chen BC; Grahn TH; Zhao YR; Bao HL; Zhu YF; Zhang QY
Liver Int; 2016 Dec; 36(12):1836-1847. PubMed ID: 27246112
[TBL] [Abstract][Full Text] [Related]
23. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
25. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
26. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
27. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
29. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
30. Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis.
Xu Q; Dou C; Liu X; Yang L; Ni C; Wang J; Guo Y; Yang W; Tong X; Huang D
Biomed Pharmacother; 2018 Nov; 107():1692-1704. PubMed ID: 30257387
[TBL] [Abstract][Full Text] [Related]
31. Ras related GTP binding D promotes aerobic glycolysis of hepatocellular carcinoma.
Ding L; Liang X
Ann Hepatol; 2021; 23():100307. PubMed ID: 33434687
[TBL] [Abstract][Full Text] [Related]
32. A feedback loop between NONHSAT024276 and PTBP1 inhibits tumor progression and glycolysis in HCC by increasing the PKM1/PKM2 ratio.
Li Y; Chen X; Huang H; Liao L; Chong H; Li G; Yuan T; Lu W; Deng S; Huang Q
Cancer Sci; 2023 Apr; 114(4):1519-1540. PubMed ID: 36529521
[TBL] [Abstract][Full Text] [Related]
33. CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma.
Huang Y; Zhu Y; Yang J; Pan Q; Zhao J; Song M; Yang C; Han Y; Tang Y; Wang Q; He J; Li Y; He J; Chen H; Weng D; Xiang T; Xia JC
Cell Death Dis; 2022 Mar; 13(3):251. PubMed ID: 35304440
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma.
Ng KT; Yeung OW; Liu J; Li CX; Liu H; Liu XB; Qi X; Ma YY; Lam YF; Lau MY; Qiu WQ; Shiu HC; Lai MK; Lo CM; Man K
Int J Oncol; 2020 Oct; 57(4):956-966. PubMed ID: 32945373
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
36. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway.
Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J
Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834
[TBL] [Abstract][Full Text] [Related]
37. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
38. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1.
Hua S; Lei L; Deng L; Weng X; Liu C; Qi X; Wang S; Zhang D; Zou X; Cao C; Liu L; Wu D
Oncogene; 2018 Mar; 37(12):1624-1636. PubMed ID: 29335523
[TBL] [Abstract][Full Text] [Related]
39. PAK2-c-Myc-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect.
Gupta A; Ajith A; Singh S; Panday RK; Samaiya A; Shukla S
Cell Death Dis; 2018 Aug; 9(8):825. PubMed ID: 30068946
[TBL] [Abstract][Full Text] [Related]
40. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway.
Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
